ECCMID 2019
AWG Member Company Participation at ECCMID 2019
Twelve AWG member companies present data from their clinical and research programs at the 29th annual meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2019) in Amsterdam, Netherlands, April 13 – 16, 2019. In addition to poster & oral presentations, representatives from AWG member companies will participate in various panels and symposiums addressing the state of the antimicrobial development pipeline.
ECCMID is an annual scientific meeting that brings together the leading experts in the fields of clinical microbiology, infectious disease and infection control from across the globe to present and discuss the latest developments in the laboratory and in the clinic to advance research in a wide array of infectious diseases.
Saturday, April 13th
Oral Abstract Session: Issues in antifungal treatment
Time: 10:00 a.m. – 12:00 p.m. CET
Location: Hall H
Cidara Therapeutics:
11:36 a.m. – 11:46 a.m. CET
- #O0115 EUCAST susceptibility testing of rezafungin: MIC data for contemporary Danish clinical yeast isolates
Oral Abstract Session: Novel antimicrobial agents and discovery strategies
Time: 1:30 p.m. – 3:30 p.m. CET
Location: Hall M
Summit Therapeutics:
1:42 p.m. – 2:42 p.m. CET
- #O0520 Novel Small-Molecule Inhibitors of Bacterial Lipoprotein Transport with Potent Antimicrobial Activity against Enterobacteriaceae
Entasis Therapeutics:
3:06 p.m. – 3:17 p.m. CET
- #O0527 Discovery of a novel series of penicillin-binding protein 3 inhibitors as monotherapy for Pseudomonas aeruginosa infections: rational design of biochemical potency and bacterial permeation
Mini-oral ePoster Session: Antibacterial activity of unusual combinations
Time: 1:30 p.m. – 2:30 p.m. CET
Location: Arena 2
ContraFect Corporation:
1:48 p.m. – 1:53 p.m. CEST
- #O0200 Lysin GN123 re-sensitises carbapenem-resistant Pseudomonas aeruginosa to imipenem
Integrated Symposium: Update on acute bacterial skin and skin structure infection: current challenges and new therapeutic agents
Time: 1:30 p.m. – 3:30 p.m. CET
Location: Hall D
Melinta Therapeutics:
Mini-oral ePoster Session: Clinical trials with recently approved or late-stage development antibiotics
Time: 2:45 p.m. – 3:45 p.m. CET
Location: Arena 5
Entasis Therapeutics:
2:45 p.m. – 2:50 p.m. CET
- #O0300 A double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of intravenous sulbactam-ETX2514 in the treatment of hospitalized adults with complicated urinary tract infections, including acute pyelonephritis
Motif Bio:
2:57 p.m. – 3:02 p.m. CET
- #O0303 An efficacy analysis by lesion size of iclaprim versus vancomycin in patients with acute bacterial skin and skin structure infections: pooled phase III REVIVE trials
Paratek Pharmaceuticals:
3:09 – 3:14 a.m. CET
- #O0304 Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild to moderate renal insufficiency
3:21 – 3:26 p.m. CET
- #O0306 Safety and efficacy of omadacycline by patient body mass index for the treatment of acute bacterial skin and skin structure infections
Oral Abstract Session: Novel approaches to fungal diseases
Time: 2:45 p.m. – 3:45 p.m. CET
Location: Hall M
Amplyx:
- #O0269 In vitro activity of APX001A and comparator agents against 1706 fungal isolates collected during an international surveillance programme (2017)
Cidara Therapeutics:
3:21 p.m. – 3:31 p.m. CET
- #O0271 Rezafungin PK/PD in a mouse model of Pneumocystis pneumonia
Paper Poster Session: Clinical pharmacokinetics, treatment strategies and prescribing of antifungals
Time: 3:30 p.m. – 4:30 p.m. CET
Location: Paper Poster Area
Cidara Therapeutics:
- #P0119 Phase II STRIVE clinical trial of rezafungin for the treatment of candidemia and/or invasive candidiasis: results stratified by baseline renal function
- #P0115 Absorption, distribution and excretion of rezafungin after single-dose intravenous administration in rats and monkeys
SCYNEXIS:
- #P0125 Use of ibrexafungerp (formerly SCY-078) to treat severe azole-refractory oesophageal candidiasis: a case report from the FURI study
Paper Poster Session: Biofilm eradication strategies
Time: 3:30 p.m. – 4:30 p.m. CET
Location: Paper Poster Area
ContraFect Corporation:
- #P0528 Lysin exebacase (CF-301) exhibits potent bactericidal activity in human synovial fluid against biofilm-forming Staph epidermidis isolates
Paper Poster Session: Clinical Aspects of Community-Acquired Pneumonia and Respiratory Tract Infection
Time: 3:30 p.m. – 4:30 p.m. CET
Location: Paper Poster Area
Paratek Pharmaceuticals:
- #P0485 Early clinical response and clinical stability as predictors of overall clinical response in community-acquired bacterial pneumonia
Nabriva Therapeutics:
- #P0478 Microbiology and outcomes among patients hospitalized with community-onset pneumonia: a multi-centre retrospective cohort study
- #P0479 Culture-positive patients hospitalised with community-onset pneumonia have worse outcomes than those with negative or no culture: a multi-centre retrospective cohort study
Paper Poster Session: Other issues and diverse latebreaker aspects
Time: 3:30 p.m. – 4:30 p.m. CET
Location: Paper Poster Area
SCYNEXIS:
- #L0028Successful Treatment of Two Patients with Candida auris Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078) from the CARES Study
- #L0033 Favorable Clinical Outcome of Two Patients with Candida spp Spondylodiscitis treated with Oral Ibrexafungerp (formerly SCY-078) from the FURI Study
Melinta Therapeutics:
- #L0041 Activity of meropenem-vaborbactam and single-agent comparators against KPC-producing Enterobacterales isolates from European countries (2016-2018) stratified by infection type
Sunday, April 14th
Oral Session: Unconventional approaches to skin infections
Time: 10:00 a.m. – 12:00 p.m. CET
Location: Hall L
Melinta Therapeutics:
- #O0435 Development and validation of a risk stratification score for mixed Gram-negative and Gram-positive infections among patients hospitalized with skin and skin structure infections in the USA
Pipeline Corner: Therapeutics pipeline corner
Time: 12:15 p.m. – 1:15 p.m. CET
Location: Arena 3
ContraFect Corporation:
Entasis Therapeutics
Summit Therapeutics
Paper Poster Session: New beta-lactamase inhibitors: in vitro studies
Time: 1:30 p.m. – 2:30 p.m. CET
Location: Paper Poster Area
Entasis Therapeutics:
- #P1184 The novel beta-lactamase inhibitor ETX1317 effectively restores the activity of cefpodoxime against recent global Enterobacteriaceae isolates from urinary tract infections
- #P1185 The novel beta-lactamase inhibitor ETX2514 effectively restores sulbactam activity against recent global Acinetobacter baumannii-calcoaceticus complex clinical isolates
- #P1186 The susceptibility of global isolates of Acinetobacter baumannii to ETX2514SUL and comparators
VenatoRx Pharmaceuticals:
- #P1175 Antimicrobial activity of cefepime in combination with VNRX-5133 against a global 2018 surveillance collection of clinical isolates
- #P1176 Antimicrobial activity of cefepime in combination with VNRX-5133 against a collection of beta-lactamase-producing Enterobacteriacea
- #P1177 Activity of cefepime/VNRX-5133 and comparators against an Italian nationwide collection of Pseudomonas aeruginosa from respiratory and bloodstream infections
- #P1178 VNRX-5133 maintains potent inhibitory activity in engineered NDM-1 variants with increased cefepime hydrolytic efficiency
- #P1179 Evaluation of the in vitro activity of cefepime plus VNRX-5133 and comparative agents against carbapenem-resistant Enterobacteriaceae
- #P1180 In vitro activity of the orally available ceftibuten/VNRX-7145 combination against a challenge set of Enterobacteriaceae pathogens carrying molecularly characterised beta-lactamase genes
- #P1181 Selection of ceftibuten as the partner antibiotic for the oral beta-lactamase inhibitor VNRX-7145.
- #P1182 Ceftibuten/VNRX-7145, an orally bioavailable beta-lactam/beta-lactamase inhibitor combination active against serine-beta-lactamase producing Enterobacteriaceae.
- #P1183 Oral ceftibuten/VNRX-7145 shows equivalent activity in vitro to IV therapeutics against MDR Enterobacteriaceae.
Monday, April 15th
Mini-oral ePoster Session: Antifungals: novel drugs, novel dosing?
Time: 11:00 a.m. – 12:00 p.m. CET
Location: Arena 2
Cidara Therapeutics:
11:48 a.m. – 11:53 a.m. CET
- #O0741 Rezafungin is more effective than micafungin in treating of FKS-mutant Candida glabrata intra-abdominal candidiasis
Amplyx:
11:06 a.m. – 11:11 a.m. CET
- #O0734 APX001 protects immunosuppressed mice from scedosporiosis
SCYNEXIS:
11:00 a.m. – 11:05 a.m. CET
- #O0733 Efficacy of ibrexafungerp (formerly SCY-078) against Pneumocystis pneumonia in a murine therapeutic model
11:42 a.m. – 11:47 a.m. CET
- #O0740 Penetration of ibrexafungerp (formerly SCY-078) versus micafungin at the site of infection in an intra-abdominal candidiasis mouse model
Paper Poster Session: Sexually transmitted infections complicated by antimicrobial resistance
Time: 12:30 p.m. – 1:30 p.m. CET
Location: Paper Poster Area
Iterum Therapeutics:
- #P1705 In vitro activity of sulopenem against resistant Neisseria gonorrhoeae
Paper Poster Session: Diverse methodologies for MIC testing in Gram-negatives
Time: 12:30 p.m. – 1:30 p.m. CET
Location: Paper Poster Area
Melinta Therapeutics:
- #P1738 Multi-centre evaluation of meropenem/vaborbactam MIC results for Enterobacteriaceae using MicroScan Dried Gram-negative MIC panels
- #P1741 ETEST meropenem/vaborbactam for antimicrobial susceptibility testing of Enterobacterales and Pseudomonas aeruginosa: performance results from a multi-centre study
Nabriva Therapeutics:
- #P1733 Lack of agreement between fosfomycin susceptibility testing methods against clinical Pseudomonas aeruginosa isolates
Paper Poster Session: Urinary tract infections
Time: 12:30 p.m. – 1:30 p.m. CET
Location: Paper Poster Area
Iterum Therapeutics:
- #P1656 A patient-specific clinical predictive model to anticipate the risk of treatment failure in uncomplicated urinary tract infections
Oral Abstract Session: New therapeutic strategies in viral infections
Time: 1:30 p.m. – 3:30 p.m. CET
Location: Hall M
Cidara Therapeutics:
2:18 p.m. – 2:28 p.m. CET
- #O0818 Cloudbreak: a novel approach for the treatment and prevention of influenza virus
Paper Poster Session: In vitro activity of investigational antibacterial agents
Time: 1:30 p.m. – 2:30 p.m. CET
Location: Paper Poster Area
Cidara Therapeutics:
- #P1821 Novel Cloudbreak bifunctional molecule protects against Acinetobacter pneumonia
Nabriva Therapeutics:
- #P1823 Antimicrobial activity of lefamulin against a large longitudinal collection of clinical bacterial isolates collected worldwide: results from the SENTRY antimicrobial surveillance program
- #P1828 In vitro activity of lefamulin against isolates commonly causing community-acquired bacterial pneumonia collected during the SENTRY surveillance programme 2017 in Europe
Paper Poster Session: In vitro activity of newer antibacterial agents
Time: 1:30 p.m. – 2:30 p.m. CET
Location: Paper Poster Area
Paratek Pharmaceuticals:
- #P1876 In vitro activity of omadacycline and comparators against Gram-positive and -negative clinical isolates collected in 2018 from patients in European medical centres: SENTRY surveillance program results
Melinta Therapeutics:
- #P1885 Delafloxacin tentative ECOFF values for common Gram-positive and Gram-negative bacteria
- #P1882 Oritavancin activity against Staphylococcus aureus clinical isolates causing serious infections in hospitalised patients in Europe (2017-2018)
Motif Bio:
- #P1884 Surveillance of iclaprim activity against Gram-positive cocci, including antibiotic-resistant strains, collected from patients with skin and skin structure infections during 2017 from European and American hospitals
Paper Poster Session: Clinical efficacy studies for antimicrobial agents
Time: 1:30 p.m. – 2:30 p.m. CET
Location: Paper Poster Area
Paratek Pharmaceuticals:
- Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia
Paper Poster Session: Recent research on the pharmacokinetics and safety of antibacterial agents
Time: 1:30 p.m. – 2:30 p.m. CET
Location: Paper Poster Area
Paratek Pharmaceuticals:
- #P1943 Omadacycline pharmacokinetics: impact of comorbidities
- #P1944 Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI)
Entasis Therapeutics:
- #P1953 Population pharmacokinetic and pharmacokinetic-pharmacodynamic target attainment analyses of ETX2514SUL to support dosing regimens in patients with varying renal function
Nabriva Therapeutics:
- #P1945 Population pharmacokinetic analysis for lefamulin using data from healthy volunteers and infected patients
- #P1946 Pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses to support lefamulin dose justification and susceptibility breakpoint determinations for patients with community-acquired bacterial pneumonia (CABP)
VenatoRx Pharmaceuticals:
- #P1951 Pharmacokinetics of VNRX-5133 alone and combined with cefepime when co-administered with metronidazole
Paper Poster Session: Safety of Antibacterial Agents in the Clinic
Time: 1:30 p.m. – 2:30 p.m. CET
Location: Paper Poster Area
Paratek Pharmaceuticals:
- #P2011 Omadacycline hepatic safety: integrated analysis of randomized controlled phase III trials
Paper Poster Session: Evaluation of diverse antimicrobials in vitro and experimental models
Time: 1:30 p.m. – 2:30 p.m. CET
Location: Paper Poster Area
Iterum Therapeutics:
- #P1992 Post-antibiotic and sub-inhibitory minimum inhibitory concentration effects of sulopenem
Entasis Therapeutics:
- #P1991: Efficacy of Cefpodoxime proxetil and ETX0282 in a murine UTI model with E. coli and K. pneumoniae
Integrated Symposium: Light and shadows in the management of serious multidrug-resistant Gram-negative infections
Time: 4:00 p.m. – 6:00 p.m. CET
Location: Hall F
Melinta Therapeutics:
Tuesday, April 16th
Oral Session: Recent clinical trials
Time: 11:00 a.m. – 12:00 p.m. CET
Location: Hall N
ContraFect Corporation:
11:24 a.m. – 11:34 a.m. CEST
- # L0012 Exebacase (Lysin CF-301) improved clinical responder rates in methicillin-resistant Staphylococcus aureus (MRSA) bacteremia including endocarditis compared to standard of care antibiotics alone in a first-in patient Phase 2 study
SCYNEXIS:
- #L0010 Favourable Response to Oral Ibrexafungerp (formerly SCY-078) in Patients with Refractory Fungal Diseases, Interim Analysis by Pathogen from a Phase 3 Open-label Study (FURI)
Mini-oral ePoster Session: Defining exposure, efficacy and safety of new antimicrobial agents
Time: 11:00 a.m. – 12:00 p.m. CET
Location: Arena 2
Amplyx:
- #O1066 In vivo pharmacodynamic evaluation of the novel antifungal agent APX001 in a murine model of invasive pulmonary aspergillosis against wild-type and Cyp51 mutant Aspergillus fumigatus strains
Nabriva Therapeutics:
- #O1068 Oral lefamulin demonstrates favorable safety and tolerability in adults with community-acquired bacterial pneumonia in the phase III lefamulin evaluation against pneumonia (LEAP 2) study
VenatoRx Pharmaceuticals:
- #O1061 Pharmacodynamics of VNRX-5133 in combination with cefepime studied in an in vitro model of infection
- #O1064 In vivo pharmacodynamic profile of cefepime in combination with VNRX-5133 against serine beta-lactamase-producing Gram-negative bacteria in the neutropenic murine thigh infection model
Paper Poster Session: Virulence and outcomes of fungal infections
Time: 12:30 p.m. – 1:30 p.m. CET
Location: Paper Poster Area
Cidara Therapeutics:
- #P2284 Outcomes in Europe from the STRIVE clinical trial of rezafungin treatment of candidemia and/or invasive candidiasis
Paper Poster Session: Antifungal susceptibility and resistance in yeast and molds from around the world
Time: 12:30 p.m. – 1:30 p.m. CET
Location: Paper Poster Area
Cidara Therapeutics:
- #P2174 EUCAST reference testing of rezafungin susceptibility: impact of choice of plastic plates
- #P2161 Activity of rezafungin against common and rare Candida species in vitro
Paper Poster Session: Skin and Soft Tissue Infections
Time: 12:30 p.m. – 1:30 p.m. CET
Location: Paper Poster Area
Paratek Pharmaceuticals:
- #P2288 Incidence of emergency department visits and hospitalisations after outpatient treatment with an oral antibiotic among patients with acute bacterial skin and skin structure infections
Motif Bio:
- #P2287 Iclaprim versus vancomycin for patients with acute bacterial skin and skin structure infection complicated by Staphylococcus aureus or streptococcal bacteraemia: a pooled analysis of the phase III REVIVE trials
Paper Poster Session: Disk diffusion susceptibility testing
Time: 12:30 p.m. – 1:30 p.m. CET
Location: Paper Poster Area
Melinta Therapeutics:
- #P2781 An FDA-approved study for an AST disc 510(k) submission: comparison of an oxoid AST disc to a predicate AST disc for meropenem-vaborbactam
Oral Abstract Session: PK/PD to guide dosing in special populations
Time: 1:30 p.m. – 3:30 p.m. CET
Location: Hall L
Motif Bio:
- #O1162 Pharmacokinetics of iclaprim by age, weight, race and renal/hepatic function in patients with acute bacterial skin and skin structure infections: phase III REVIVE trials